Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Management of Metastatic Neck Nodes in N2/3 Hypopharyngeal Squamous Cell Carcinoma
NCT05494190Recruiting
- Sponsor
- Eye and ENT Hospital of Fudan University
- Start
- Nov 2022
- Primary completion
- Nov 2027
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of docetaxel, cisplatin and capecitabine in hypopharyngeal squamous cell carcinoma (HSCC) (2 arms), sponsored by Eye and ENT Hospital of Fudan University. Primary endpoint: Progression-free survival rate at 3 years. Started Nov 2022; status: recruiting.
02
Drugs
docetaxelcisplatincapecitabine
03
Conditions
hypopharyngeal squamous cell carcinoma (HSCC)
Beyond the preview
Go deeper on NCT05494190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05494190.